carbapenem


Also found in: Medical, Wikipedia.

car·ba·pen·em

 (kär′bə-pĕn′əm)
n.
Any of several semisynthetic or synthetic beta-lactam antibiotics that are used chiefly to treat serious infections caused by bacteria that are resistant to other antibiotics.

[carba-, alteration of carbon + penem, kind of beta-lactam with a double bond (alteration of penam, similar beta-lactam with a single bond, influenced by -ene).]
References in periodicals archive ?
Klebsiella pneumoniae are resistant to the carbapenem antibiotics that represent the last line of defence in treating infections, and are therefore regarded as extremely drug resistant (XDR).
Klebsiella pneumoniae are resistant to the carbapenem antibiotics - the last line of defence to treat infections - and are seen as extremely drug resistant.
It was less than a decade after the introduction of carbapenem and or cephalosporin in the clinical practice, in 1980's that Gram negative bacteria have become resistant to these agents (Datta and Wattal, 2010).
These results reveal two aspects: climatic factors significantly contribute to the prediction of AMR in different types of healthcare systems and societies, while climate change might increase AMR transmission, in particular, carbapenem resistance."
False positive results in inhibitor based tests occur because in the presence of EDTA, oxacillinases are converted to a less active state leading to augmentation of the inhibition zone around the carbapenem disk and reduction of carbapenem MICs.
Keywords: Carbapenem, Carbapenemases, Healthcare workers, Modified hodge test.
Pseudomonas aeruginosa (18%) showed highest susceptibility to 87% Sensitivity to Cefepime Tazobactam, Cefepime, Carbapenem and Amikacin followed by 70% Sensitivity to Piperacillin Tazobactam and Cefoperazone sulbactam.
Carbapenem resistance meant imipenem and meropenem MIC [greater than or equal to]4mg/L.
There are several different mechanisms by which Enterobacteriaceae can develop resistance to carbapenem antibiotics.
(Poster 1348, Friday, October 5) The Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE) studied the in vitro activity of plazomicin against a collection of 697 carbapenem resistant Klebsiella pneumoniae, including isolates containing Klebsiella pneumoniae carbapenemase (KPC) and OXA carbapenemase, from 9 healthcare systems.
Previous studies on carbapenem-resistant ACB complex in Taiwan reported that the risk factors associated with the isolation of carbapenem-resistant ACB complex were carbapenem use, duration of hospital stay, and admission in ICU.[1],[6],[13] The current study revealed that previous fluoroquinolone use is the only factor associated with the isolation of carbapenem-resistant ACB complex.
This happened irrespective of the recent introduction of carbapenem drugs, 11 years ago in Gaza Strip hospitals.